Strategic Partnerships Position TechnoVax to accelerate commercial traction through co-development and manufacturing partnerships that leverage the VLP platform for rapid vaccine development and potential licensing deals, building on existing collaborations with Innovative Biotech and Innobiotech.

Funding and Investors Leverage non-dilutive funding and NIH SBIR programs to de-risk development and attract strategic investors, highlighting near-clinical status and prior grant track record to support cost-shared collaboration opportunities.

Global Distribution The inhaled powder vaccine concept with cold-chain independence enables partnerships with governments, NGOs, and distributors aiming to expand vaccine access in developing regions and streamline logistics.

Lean Operations Capitalize on a lean team by outsourcing R&D, clinical development, and manufacturing to CROs and CMOs to scale efficiently while maintaining speed to clinic and reducing internal overhead.

Pipeline Value Three lead candidates across universal flu, inhaled powder flu, and RSV offer multiple collaboration angles from co-development to licensing with large pharma and vaccine manufacturers seeking novel VLP-enabled platforms and pandemic-ready solutions.